Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study. J of Skin [Internet]. 2020 Sep. 2 [cited 2025 Apr. 19];4(5):s67. Available from: https://skin.dermsquared.com/skin/article/view/1016